Amelioration of Radiation-Induced Damages in Mice by Curcuminoids: The Role of Bioavailability

Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with a special reference to the recent hepatotoxic reports of curcumin supplements: A 90-days prospective study

“…Once swell in the gastrointestinal tract, CGM has been shown to act as a self-emulsifying hydrogel with high mucoadhesive character, capable of delivering amphiphilic colloidal curcumin particles that can be absorbed quickly. CGM has already demonstrated its superior efficacy in a relatively low dosage [ [32] , [33] , [34] ], with improved brain bioavailability as revealed by its influence on brain waves [ 35 ], radioprotective [ 36 ] and neuroprotective effects [ 37 , 38 ]. CGM was reported to exhibit 45-fold enhancement in the bioavailability of free curcuminoids and 270-fold enhancement in the bioavailability of total curcuminoids (sum of conjugated and unconjugated), when compared to an equivalent dose of unformulated standard curcuminoids with 95 % purity [ 31 ].…”

“…wt.) in Swiss albino mice showed no signs of genotoxicity, DNA damage or chromosomal aberrations among CGM treated animals [ 36 ].…”

Review: bioavailability and efficacy of ‘free’ curcuminoids from curcumagalactomannoside (CGM) curcumin formulation

“…The CGM group also showed higher levels of antioxidant enzymes (21% reduced hepatic GPx activity compared with 25% in unformulated curcumin and 42% in radiation control group) and prevented the radiation-induced increase in lipid peroxidation and infiltration of inflammatory exudates in intestinal mucosa. Furthermore, CGM treatment reduced the degree of chromosomal defects and DNA damage and yielded a better survival rate compared with unformulated curcumin (4-fold reduction in DNA damage in CGM, p < 0•05 compared with 2•5-fold in USC group, p < 0•01 and 83% reduction in radiation-induced chromosomal aberration in CGM vs 66% in USC group, p < 0•05) (118) . Depending on the type, size, location of cancer and/or goal of the radiation therapy, multiple consecutive treatments may be required ('Targeted Therapy to Treat Cancer', originally published by the National Cancer Institute, 30 March 2022); thus, the single exposure to radiation used in this study may be considered a limitation of its translatability to clinical trials.…”

“…There are opposing views regarding the use of supplementation with antioxidants during radiation therapy, with some radiation oncologists advising against it for fear that cancer cells may also benefit and render radiation less effective, but antioxidants can reduce the side effects of radiation therapy in normal cells (117) . A recent study evaluated the radioprotective effects of CGM in an animal model of radiation-induced damage (118) . Ionising gamma radiation significantly reduces leucocytes and bone marrow cells and increases formation of cytotoxic reactive oxygen and nitrogen species as well as genetic instability.…”